Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

Highlights

– In a retrospective, real‑world cohort of 4,241 women with self‑reported PCOS and overweight/obesity, tirzepatide treatment was associated with a mean 18.81% weight loss at 10 months.

– High engagement with a digital weight‑loss platform (monthly coaching, monthly app use, weekly weight tracking) correlated with greater mean weight loss (21.02% vs 17.23%).

– By 10 months, 96.6% of participants lost ≥5% body weight and 90.1% lost ≥10% body weight; however, the study lacked biochemical reproductive or cardiometabolic outcomes and was limited by self‑reporting and selection bias.

Background: PCOS, obesity, and the treatment gap

Polycystic ovary syndrome (PCOS) affects an estimated 5–10% of reproductive‑age women and is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Excess adiposity commonly co‑exists with PCOS and amplifies insulin resistance, dyslipidemia, menstrual irregularity, infertility, and long‑term cardiovascular risk. Weight loss remains first‑line therapy, with modest losses (5–10%) improving menstrual regularity, hyperandrogenic symptoms, and metabolic markers, while larger losses confer greater benefits.

Recently developed incretin‑based therapies, including the dual glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptor agonist tirzepatide, have produced substantial weight reductions in randomized obesity trials. However, specific evidence in women with PCOS has been limited. The real‑world analysis presented at Obesity Week 2025 is the largest dataset to date describing tirzepatide’s weight effect in this subgroup and raises clinical and research questions about translating weight loss into reproductive and cardiometabolic benefit.

Study design and population

The analysis reported by David R. Huang, MBBS, used retrospective data from a London‑based digital weight‑loss service (Voy) that combines prescription medication with an app, coaching, and remote support. Inclusion criteria for the presented cohort were self‑reported PCOS and initiation of tirzepatide between February 2024 and January 2025, with baseline body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 plus at least one comorbidity.

Key cohort descriptors: n=4,241 women, mean age 34 years, median baseline BMI 35.6 kg/m2. Outcomes were derived from routinely collected program data, including weight measures logged in the app, and digital engagement was defined as participation in monthly coaching, monthly app use, and weekly weight tracking.

Key findings

Primary weight outcomes at 10 months:

• Mean percent weight loss: 18.81% (reported as highly significant).
• Proportion achieving clinically meaningful weight loss: 96.6% lost ≥5% of body weight and 90.1% lost ≥10%.
• Effect of digital engagement: participants meeting the digital engagement definition lost a mean 21.02% versus 17.23% among those not meeting engagement criteria.

These effects are numerically large and, if confirmed in controlled settings, would represent a transformational magnitude of weight loss for many women with PCOS. For context, conventional lifestyle interventions often yield mean weight losses of 5–10% at 6–12 months, and prior pharmacotherapies (e.g., liraglutide, semaglutide) produced variable outcomes in PCOS‑targeted trials.

Safety and tolerability data

The abstract and presentation focused on weight outcomes; detailed safety and adverse event reporting were not provided in the meeting summary. In phase 3 obesity and diabetes trials of tirzepatide, gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) were the most common. Rare but serious events under class surveillance include pancreatitis, gallbladder disease, and a rodent‑model signal for C‑cell thyroid tumors; these risks are discussed in regulatory prescribing information and require clinical vigilance.

Interpretation and limitations

The magnitude of weight loss reported is striking, but several caveats temper interpretation:

• Study design: retrospective, uncontrolled, and drawn from a digital health population. Such cohorts are vulnerable to selection bias (motivated patients who enroll in paid services), survivorship bias, and missing data.
• PCOS ascertainment: diagnosis was self‑reported rather than confirmed by standardized clinical or biochemical criteria (Rotterdam or other criteria), raising the risk of misclassification.
• Outcome measures: weight was collected via app entry (likely from user‑reported scales); objective verification (clinic weights, standardized scales) and blinded assessments were absent.
• Absence of biomarkers: the study did not report reproductive outcomes (ovulation, menstrual regularity), androgen levels, insulin sensitivity markers, lipid changes, or pregnancy outcomes. As the session moderator noted, it is unknown whether weight loss translated into improvements in core PCOS pathophysiology.
• Safety reporting: granular adverse event data were not presented. Real‑world patients may experience side effects affecting adherence and clinical outcomes.

Given these limitations, the dataset is hypothesis‑generating rather than practice‑changing. It supports the signal that tirzepatide can produce large weight loss in women with PCOS but cannot on its own define effects on fertility, menstrual function, hyperandrogenism, or long‑term cardiometabolic risk.

Biological plausibility and mechanistic considerations

Tirzepatide activates both GIP and GLP‑1 receptor pathways. GLP‑1 receptor agonism reduces appetite, slows gastric emptying, and promotes satiety; GIP receptor agonism may enhance insulin secretion and has complex central and peripheral metabolic effects. The combined incretin agonism appears to produce greater weight reductions than GLP‑1 receptor agonists alone in randomized trials of people with obesity, which provides biologic plausibility for the large effects observed in this PCOS cohort.

In PCOS, where insulin resistance and altered appetite regulation often contribute to weight accrual, pronounced weight loss could plausibly improve insulin sensitivity, reduce hyperandrogenism, and restore ovulatory cycles. However, incretin therapies may also have direct or indirect effects on reproductive hormones or ovarian function that are incompletely characterized; this underscores the need for mechanistic studies in PCOS populations.

Clinical implications and practical guidance

For clinicians treating women with PCOS and overweight or obesity, the real‑world data highlight tirzepatide as a potentially powerful option for weight reduction. Practical considerations include:

• Patient selection: consider tirzepatide for women with PCOS and clinically significant obesity (e.g., BMI ≥30 or ≥27 with comorbidity) who have not achieved adequate response to lifestyle interventions and for whom rapid, substantial weight loss is indicated.
• Reproductive planning: tirzepatide is not indicated during pregnancy; counsel patients on effective contraception while on therapy and stop treatment when planning pregnancy. Discuss the unknowns regarding effects on ovulation and fertility—weight loss may improve fertility, but specific data on tirzepatide are lacking.
• Baseline evaluation and monitoring: assess glycemic status, lipids, liver enzymes, pregnancy status, and gallbladder history prior to initiation; monitor weight, adverse effects (particularly gastrointestinal), glucose/insulin measures as clinically indicated, and mental health. Document PCOS phenotype and relevant reproductive endpoints if used in this population.
• Multidisciplinary care: integrate endocrinology, obstetrics/gynecology, nutrition, and behavioral support. The observed amplification of effect with digital engagement suggests combining pharmacotherapy with structured behavioral and digital support may enhance outcomes.
• Cost and access: tirzepatide (approved formulations for diabetes and for weight management) may have substantial out‑of‑pocket cost depending on insurance coverage and indication; consider these factors in shared decision‑making.

Research priorities

To establish the role of tirzepatide in PCOS management, the following studies are needed:

• Randomized controlled trials enrolling phenotyped women with PCOS, with coprimary endpoints including reproductive outcomes (ovulation rate, pregnancy/live birth rate), androgen levels, menstrual regularity, and validated metabolic endpoints (insulin sensitivity, lipids, blood pressure).
• Mechanistic studies assessing effects on ovarian steroidogenesis, gonadotropin secretion, and central appetite/reward pathways in PCOS.
• Prospective safety studies and pregnancy registries to document maternal and fetal outcomes after exposure and to clarify any teratogenic or perinatal risks.
• Comparative effectiveness research to position tirzepatide relative to other GLP‑1 receptor agonists, bariatric surgery, and multimodal lifestyle programs in PCOS cohorts.

Conclusion

The large retrospective cohort of women with self‑reported PCOS treated with tirzepatide reported impressive mean weight loss (≈19% at 10 months) and high rates of clinically meaningful weight reductions. Digital engagement appeared to augment outcomes. While the findings are encouraging and biologically plausible given tirzepatide’s incretin actions, the study’s retrospective and self‑reported nature, absence of validated PCOS diagnosis and biochemical endpoints, and lack of detailed safety data mean that randomized, biomarker‑driven trials are required to determine whether weight loss translates into improved reproductive and long‑term cardiometabolic outcomes in PCOS.

Clinicians should weigh the potential benefits of substantial weight loss against unknown reproductive‑specific effects and known drug class adverse events, counsel patients carefully regarding pregnancy planning and contraception, and consider combined behavioral and digital support to maximize treatment response.

Funding and clinicaltrials.gov

The analysis was conducted using data from a commercial digital weight‑loss service (Voy); specific funding sources were not reported in the meeting summary. No clinicaltrials.gov identifiers were provided for this retrospective analysis. Ongoing and future randomized trials of tirzepatide for obesity and metabolic disease are listed on public registries and industry pipelines.

References

1. Teede HJ, Misso ML, Costello MF, et al. International evidence‑based guideline for the assessment and management of polycystic ovary syndrome 2018. Human Reproduction Open. 2018;2018(2):hoy004. (International PCOS guideline — management priorities include weight loss for women with overweight/obesity.)

2. Wilding JPH, Batterham RL, Calanna S, et al. Once‑weekly tirzepatide for weight loss in adults with obesity. N Engl J Med. 2022;387(3):205–216. (Phase 3 randomized trial program showing substantial weight loss with tirzepatide in people with obesity.)

3. U.S. Food and Drug Administration. FDA approves Zepbound (tirzepatide) for chronic weight management in adults with obesity or overweight with at least one weight‑related condition. U.S. FDA news release; November 2023. (Regulatory approval information and prescribing considerations.)

4. Prescribing information and safety communications for tirzepatide (Mounjaro/Zepbound) and class guidance should be consulted for up‑to‑date adverse event profiles and contraindications.

Note: The cohort data summarized in this article were reported by David R. Huang, MBBS, at Obesity Week 2025; the presentation constituted a real‑world retrospective analysis of patients enrolled in the Voy digital program between February 2024 and January 2025.